Post by FDA

Today, the FDA approved vepdegestrant (Veppanu, Pfizer, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. https://lnkd.in/eEKZ4Vy6   The prescribing information includes warnings and precautions for QTc interval prolongation and embryo-fetal toxicity.     Learn more in the FDA-approved prescribing information at:  https://lnkd.in/emUfeBq